Insider · CIK 0001578888
Nicholas Glover
Files at LITS (MEI Pharma, Inc.). First filing -, latest -.
In brief
Nicholas Glover files SEC Form 4 as director at LITS (MEI Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Nicholas Glover has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 14, 2025 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | - | - | 55,000 | Nov 19, 2025 |
| Jul 15, 2025 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jul 17, 2025 |
| Sep 29, 2023 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Oct 12, 2023 |
Questions about Nicholas Glover
Answered from the filings on this page, as of the latest one.
Is Nicholas Glover buying or selling?
Nicholas Glover has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Nicholas Glover's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nicholas Glover has 0.
Where does Nicholas Glover file Form 4?
Nicholas Glover has filed Form 4 at LITS (MEI Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.